SCHEMBL6109

SCHEMBL6109

CS(=O)(=O)NC(=O)CCCc1ccc(OCc2cccc3cccnc23)cc1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADAM17 P78536 2/20 0.54
MMP2 P08253 1/20 0.54
MMP9 P14780 1/20 0.54
MTNR1A P48039 2/20 0.48
MTNR1B P49286 2/20 0.48
MEN1 O00255 1/20 0.48
KMT2A Q03164 1/20 0.48
MMP1 P03956 1/20 0.46
HDAC6 Q9UBN7 1/20 0.44
CYP4F2 P78329 1/20 0.44
CYP4A11 Q02928 1/20 0.44
FFAR1 O14842 2/20 0.43
AKR1B1 P15121 1/20 0.43
LTA4H P09960 1/20 0.42
PLG P00747 1/20 0.41
PRSS1 P07477 1/20 0.41
PRSS2 P07478 1/20 0.41
PRSS3 P35030 1/20 0.41
LMNA P02545 1/20 0.41
MAPT P10636 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11898793 0.79 CYP4F2 (0.51) MEN1KMT2ACYP4F2CYP4A11LTA4H
SCHEMBL5797 0.79 EPHX2 (0.53) CYP4F2CYP4A11FFAR1LTA4H
SCHEMBL11898956 0.77 ADAM17 (0.50) ADAM17MMP2MMP9MEN1KMT2A
SCHEMBL10689 0.77 CYSLTR1 (0.66) FFAR1AKR1B1
SCHEMBL6158 0.75 LTA4H (0.46) ADAM17MMP2MMP9MMP1CYP4F2
SCHEMBL11899994 0.75 LTA4H (0.61) FFAR1LTA4HLMNA
SCHEMBL11943 0.74 FFAR1 (0.54) FFAR1LMNAMAPT
SCHEMBL12049 0.74 LTA4H (0.50) CYP4F2CYP4A11FFAR1LTA4HLMNA
SCHEMBL5860 0.74 FFAR1 (0.67) FFAR1MAPTHPGD
SCHEMBL6073 0.73 L3MBTL1 (0.56) MEN1KMT2AMMP1HDAC6CYP4F2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140364398-A1 C-Linked Hydroxamic Acid Derivatives Useful As Antibacterial Agents PFIZER INC. (US) 2014-12-11 US disclosed
US-8853258-B2 C-linked hydroxamic acid derivatives useful as antibacterial agents PFIZER INC. (US) 2014-10-07 US disclosed
EP-2488489-A2 C-LINKED HYDROXAMIC ACID DERIVATIVES USEFUL AS ANTIBACTERIAL AGENTS Pfizer Inc. (US) 2012-08-22 EP disclosed
US-20120202777-A1 C-Linked Hydroxamic Acid Derivatives Useful As Antibacterial Agents BROWN MATTHEW FRANK (US) 2012-08-09 US disclosed
WO-2011045703-A2 C-LINKED HYDROXAMIC ACID DERIVATIVES USEFUL AS ANTIBACTERIAL AGENTS PFIZER INC. (US) 2011-04-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120202777-A1 C-Linked Hydroxamic Acid Derivatives Useful As Antibacterial Agents HAX1, LPXN, AGXT ADAM17 508/4885MMP2 360/4885MMP9 740/4885
US-20140364398-A1 C-Linked Hydroxamic Acid Derivatives Useful As Antibacterial Agents LCT, AGXT, PRXL2A ADAM17 364/4885MMP2 464/4885MMP9 586/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.